{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:22:15Z","timestamp":1787026935533,"version":"build-2736575974"},"reference-count":55,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T00:00:00Z","timestamp":1676332800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Measurable residual disease (MRD) is defined as the presence of residual cancer cells after treatment in patients with clinically undetectable disease, who would otherwise be considered in complete remission. It is a highly sensitive parameter which indicates the disease burden and predicts survival in this setting of patients. In recent years, MRD has gained a role in many hematological malignancies as a surrogate endpoint for clinical trials: undetectable MRD has been correlated to longer progression free survival (PFS) and overall survival (OS). New drugs and combinations have been developed with the aim to achieve MRD negativity, which would indicate favorable prognosis. Different methods to measure MRD have also been devised, which include flow cytometry, polymerase chain reaction (PCR) and next generation sequencing (NGS), with different sensitivity and accuracy in evaluating deep remission after treatment. In this review, we will analyze the current recommendations for the detection of MRD, with particular focus on its role in Chronic Lymphocytic Leukemia (CLL), as well as the different detection methods. Moreover, we will discuss the results of clinical trials and the role of MRD in new therapeutic schemes with inhibitors and monoclonal antibodies. MRD is not currently used in the clinical practice to evaluate response to treatment, due to technical and economical limitations, but it\u2019s gaining more and more interest in trials settings, especially since the introduction of venetoclax. The use of MRD in trials will likely be followed by a broader practical application in the future. The aim of this work is to provide a reader-friendly summary of the state of art in the field, as MRD will soon become an accessible tool to evaluate our patients, predict their survival and guide physician\u2019s therapeutic choices and preferences.<\/jats:p>","DOI":"10.3389\/fonc.2023.1112616","type":"journal-article","created":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T13:02:33Z","timestamp":1676379753000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Measurable residual disease in chronic lymphocytic leukemia"],"prefix":"10.3389","volume":"13","author":[{"given":"Giulia","family":"Benintende","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Pozzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Idanna","family":"Innocenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Autore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Fresa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"D\u2019Arena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valter","family":"Gattei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Laurenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,2,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404584","article-title":"International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia","volume":"21","author":"Rawstron","year":"2007","journal-title":"Leukemia"},{"key":"B3","article-title":"[Relevance of cytological and immunophenotypical analysis for the diagnosis of b-cell chronic lymphocytic leukaemia]","volume":"60","author":"Guillaume","year":"2002","journal-title":"Ann Biol Clin (Paris)"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-08-634816","article-title":"Eliminating minimal residual disease as a therapeutic end point: working toward cure for patients with CLL","volume":"127","author":"Thompson","year":"2016","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2013.01.005","article-title":"The role of minimal residual disease measurements in the therapy for CLL","volume":"27","author":"B\u00f6ttcher","year":"2013","journal-title":"Hematol Oncol Clin North Am"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01241-1","article-title":"Measurable residual disease in chronic lymphocytic leukemia: Expert review and consensus recommendations","volume":"35","author":"Wierda","year":"2021","journal-title":"Leukemia"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021015014","article-title":"Enduring undetectable MRD and updated outcomes in relapsed\/refractory CLL after fixed-duration venetoclax-rituximab","volume":"140","author":"Seymour","year":"2022","journal-title":"Blood"},{"key":"B8","volume-title":"The combination of ibrutinib plus venetoclax results in a high rate of MRD negativity in previously untreated CLL: The results of the planned interim analysis of the phase III NCRI FLAIR trial","author":"Hillmen","year":"2022"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-9650-6_17","article-title":"Clinical flow-cytometric testing in chronic lymphocytic leukemia","volume":"2032","author":"Salem","year":"2019","journal-title":"Methods Mol Biol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1182\/blood.V98.1.29","article-title":"Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy","volume":"98","author":"Rawstron","year":"2001","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.216","article-title":"Improving efficiency and sensitivity: European research initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL","volume":"27","author":"Rawstron","year":"2013","journal-title":"Leukemia"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-06-093906","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the international workshop on chronic lymphocytic leukemia updating the national cancer institute\u2013working group 1996 guidelines","volume":"111","author":"Hallek","year":"2008","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.313","article-title":"A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European research initiative on CLL study","volume":"30","author":"Rawstron","year":"2016","journal-title":"Leukemia"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.21595","article-title":"Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: An European research initiative on CLL (ERIC) & European society for clinical cell analysis (ESCCA) harmonisation project","volume":"94","author":"Rawstron","year":"2018","journal-title":"Cytom B Clin Cytom"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.21875","article-title":"Performance of eight-color dry antibody reagent in the detection of minimal residual disease in chronic lymphocytic leukemia samples","volume":"98","author":"Bento","year":"2020","journal-title":"Cytom B Clin Cytom"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.3197.3197","article-title":"ROR-1 is a highly discriminative marker in flow cytometric minimal residual disease (MRD) detection in chronic lymphocytic leukemia (CLL)","volume":"128","author":"Patz","year":"2016","journal-title":"Blood"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2014.92","article-title":"Minimal residual disease detection with tumor-specific CD160 correlates with event-free survival in chronic lymphocytic leukemia","volume":"5","author":"Farren","year":"2015","journal-title":"Blood Cancer J"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/hon.3037","article-title":"Flow cytometric evaluation of measurable residual disease in chronic lymphocytic leukemia: Where do we stand","author":"D\u2019Arena","year":"2022","journal-title":"Hematol Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.29","article-title":"Next generation flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma","volume":"31","author":"Flores-Montero","year":"2017","journal-title":"Leukemia"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.140","article-title":"Standardized MRD flow and ASO IGH RQ-PCR for MRD quantification in CLL patients after rituximab-containing immunochemotherapy: A comparative analysis","volume":"23","author":"B\u00f6ttcher","year":"2009","journal-title":"Leukemia"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404586","article-title":"Analysis of minimal residual disease by Ig\/TCR gene rearrangements: Guidelines for interpretation of real-time quantitative PCR data","volume":"21","author":"van der Velden","year":"2007","journal-title":"Leukemia"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3390\/jcm7090288","article-title":"New molecular technologies for minimal residual disease evaluation in b-cell lymphoid malignancies","volume":"7","author":"Dogliotti","year":"2018","journal-title":"J Clin Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14082","article-title":"Comparative analysis between RQ-PCR and digital-droplet-PCR of immunoglobulin\/T-cell receptor gene rearrangements to monitor minimal residual disease in acute lymphoblastic leukaemia","volume":"174","author":"della Starza","year":"2016","journal-title":"Br J Haematol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmoldx.2015.05.007","article-title":"Minimal residual disease detection by droplet digital PCR in multiple myeloma, mantle cell lymphoma, and follicular lymphoma","volume":"17","author":"Drandi","year":"2015","journal-title":"J Mol Diagn"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001077","article-title":"Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapy","volume":"134","author":"Thompson","year":"2019","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019003244","article-title":"CLL: Deep dive for residual cells by NGS matters","volume":"134","author":"Wendtner","year":"2019","journal-title":"Blood"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022017411","article-title":"Detecting measurable residual disease beyond 10-4 through an IGHV leader-based NGS approach improves prognostic stratification in CLL","author":"Hengeveld","year":"2022","journal-title":"Blood"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2017.16","article-title":"Next-generation sequencing indicates false-positive MRD results and better predicts prognosis after SCT in patients with childhood ALL","volume":"52","author":"Kotrova","year":"2017","journal-title":"Bone Marrow Transpl"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1515\/prilozi-2015-0015","article-title":"Recent advances in the pathogenesis and treatment of chronic lymphocytic leukemia","volume":"35","author":"Efremov","year":"2014","journal-title":"Pril (Makedon Akad Nauk Umet Odd Med Nauki)"},{"key":"B30","doi-asserted-by":"publisher","first-page":"S66","DOI":"10.1016\/S0140-6736(14)60329-9","article-title":"Independent prognostic significance of minimal residual disease status in chronic lymphocytic leukaemia","volume":"383","author":"Kwok","year":"2014","journal-title":"Lancet"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-05-502773","article-title":"Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia","volume":"122","author":"Abrisqueta","year":"2013","journal-title":"Blood"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial","volume":"376","author":"Hallek","year":"2010","journal-title":"Lancet"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1313984","article-title":"Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions","volume":"370","author":"Goede","year":"2014","journal-title":"New Engl J Med"},{"key":"B34","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"New Engl J Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30019-5","article-title":"Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study","volume":"17","author":"Stilgenbauer","year":"2016","journal-title":"Lancet Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0000000000000413","article-title":"Relevance of minimal residual disease in the era of targeted agents","volume":"25","author":"Heltai","year":"2019","journal-title":"Cancer J"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3960\/jslrt.20014","article-title":"Measurable residual disease in the treatment of chronic lymphocytic leukemia","volume":"60","author":"Uchiyama","year":"2020","journal-title":"J Clin Exp Hematop"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.4459","article-title":"Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: molecular remissions predict for durable complete responses","volume":"27","author":"Lamanna","year":"2009","journal-title":"J Clin Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.36.9348","article-title":"Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: A multivariate analysis from the randomized GCLLSG CLL8 trial","volume":"30","author":"B\u00f6ttcher","year":"2012","journal-title":"J Clin Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.39.2688","article-title":"Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: A multicenter phase II trial of the German chronic lymphocytic leukemia study group","volume":"30","author":"Fischer","year":"2012","journal-title":"J Clin Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"New Engl J Med"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.686768","article-title":"BTK inhibitors in chronic lymphocytic leukemia: Biological activity and immune effects","volume":"12","author":"Palma","year":"2021","journal-title":"Front Immunol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-12-820910","article-title":"Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study","volume":"131","author":"Ahn","year":"2018","journal-title":"Blood"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817073","article-title":"Ibrutinib\u2013rituximab or chemoimmunotherapy for chronic lymphocytic leukemia","volume":"381","author":"Shanafelt","year":"2019","journal-title":"New Engl J Med"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0276-9","article-title":"Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia\/small lymphocytic lymphoma","volume":"33","author":"Fraser","year":"2019","journal-title":"Leukemia"},{"key":"B46","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S1470-2045(18)30788-5","article-title":"Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"Moreno","year":"2019","journal-title":"Lancet Oncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000864","article-title":"Undetectable peripheral blood MRD should be the goal of venetoclax in CLL, but attainment plateaus after 24 months","volume":"4","author":"Lew","year":"2020","journal-title":"Blood Adv"},{"key":"B48","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s40273-017-0599-9","article-title":"Venetoclax for treating chronic lymphocytic leukaemia: An evidence review group perspective of a NICE single technology appraisal","volume":"36","author":"Mistry","year":"2018","journal-title":"Pharmacoeconomics"},{"key":"B49","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S1470-2045(17)30909-9","article-title":"Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: An interim analysis of a multicentre, open-label, phase 2 trial","volume":"19","author":"Jones","year":"2018","journal-title":"Lancet Oncol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1713976","article-title":"Venetoclax\u2013rituximab in relapsed or refractory chronic lymphocytic leukemia","volume":"378","author":"Seymour","year":"2018","journal-title":"New Engl J Med"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30443-5","article-title":"Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial","volume":"21","author":"Al-Sawaf","year":"2020","journal-title":"Lancet Oncol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-146161","article-title":"A randomized phase III study of venetoclax-based time-limited combination treatments (RVe, GVe, GIVe) vs standard chemoimmunotherapy (CIT: FCR\/BR) in frontline chronic lymphocytic leukemia (CLL) of fit patients: First Co-primary endpoint analysis of the international intergroup GAIA (CLL13) trial","volume":"138","author":"Eichhorst","year":"2021","journal-title":"Blood"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00807","article-title":"Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia: Primary analysis results from the minimal residual disease cohort of the randomized phase II CAPTIVATE study","volume":"39","author":"Wierda","year":"2021","journal-title":"J Clin Oncol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2809","article-title":"Pharmacological and protein profiling suggests venetoclax (ABT-199) as optimal partner with ibrutinib in chronic lymphocytic leukemia","volume":"21","author":"Cervantes-Gomez","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014488","article-title":"Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: Primary analysis of the CAPTIVATE FD cohort","volume":"139","author":"Tam","year":"2022","journal-title":"Blood"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1112616\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,14]],"date-time":"2023-03-14T12:27:07Z","timestamp":1678796827000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1112616\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,14]]},"references-count":55,"alternative-id":["10.3389\/fonc.2023.1112616"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2023.1112616","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,14]]},"article-number":"1112616"}}